Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Quell

- PMLiVE

BioNTech raises €290m for mRNA cancer vaccine platform

Funds will help lead melanoma candidate progress

- PMLiVE

UK launches subscription-style payment pilot to incentivise pharma antibiotics R&D

Pilot much more to industry liking, but devil will be in detail

- PMLiVE

Europe urged to adapt faster to gene therapy challenges

Resistance to high prices, even with novel payment models

- PMLiVE

Citryll snares €15m backing for its autoimmune disease NETs

New approach to tackling diseases such as lupus, RA

- PMLiVE

Amicus forms gene therapy manufacturing partnership with Catalent

Biotech invests to speed gene therapies into clinical trials

- PMLiVE

$450m diagnostics sale will fuel more Syncona biotech funding

Radiopharmaceuticals firm sold to Braco Imaging

- PMLiVE

Celgene says no to Mereo’s cancer drug etigilimab

UK biotech will focus on rare disease drugs

- PMLiVE

Syncona start-up Quell Therapeutics appoints chief exec

Biotech focusing on Tregs

- PMLiVE

J&J takes option on Genmab follow-up to Darzalex

Blockbuster partners look to next chapter - while takeover talk persists

- PMLiVE

Sanofi exiting Voyager gene therapy pact is ‘surprising’, says analyst

Move cuts pipeline depth, says GlobalData

- PMLiVE

Oxford Biomedica gets £53m cash injection from Novo venture arm

Cell and gene therapy specialist needs to invest to stay ahead

- PMLiVE

Novartis secures US approval – and payers’ blessing – for $2m gene therapy Zolgensma

Novel financing deal could be sector's future

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links